Generic semaglutide launches
India’s big generics push: Sun Pharma, Dr Reddy’s, Zydus Life Sciences and Glenmark have rolled out generic semaglutide injections after patent expiry — a major access shift for T2D care in a high‑burden market. Dr Reddy’s version, branded Obeda, is being priced at ₹4,200 per month and analysts expect competition to push prices lower quickly. ( )
Novo Nordisk’s key semaglutide patent in India expired on March 20, 2026, clearing the way for immediate generic launches by domestic manufacturers. (msn.com)) Industry trackers and trade outlets put more than 50 branded semaglutide generics in development or ready to launch as the patent window closed. (medicaldialogues.in)) Dr. Reddy’s said its DCGI‑approved product is supplied in 2 mg and 4 mg prefilled disposable pens and that each pen delivers a minimum of four weekly doses. (drreddys.com)) Zydus Lifesciences launched semaglutide in a reusable, adjustable‑dose pen and listed average monthly therapy cost near ₹2,200. (pharma.economictimes.indiatimes.com)) Glenmark introduced GLIPIQ with weekly treatment starting at ₹325 and offered the molecule in both vials and prefilled pen formats alongside a patient‑support programme named Sankalp. (pharma.economictimes.indiatimes.com)) Sun Pharma rolled out two brands — Noveltreat and Sematrinity — with published weekly therapy cost ranges from about ₹750 up to ₹2,000 across strengths. (sunpharma.com)) Multiple outlets report generics priced 50–90% below innovator levels, with some headlines citing monthly price points as low as about ₹1,290 in early listings. (indianexpress.com)) Commercial moves include co‑marketing deals such as Lupin’s agreement to co‑market Zydus’s semaglutide in India, signalling coordinated distribution plans as new brands enter the market. (drugstorenews.com))
